Clinical Trial Update: Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update indicates a Phase 1/2 study of dual-target GD2/B7-H3 CAR-NK cells for pediatric relapsed or refractory neuroblastoma is currently rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ganglioneuroblastoma
• High-risk Neuroblastoma
• Neuroblastoma

Drugs mentioned

• Dual-target GD2/B7-H3 CAR-NK cells

Snippet

Sponsor: Beijing Biotech | Conditions: Relapsed Neuroblastoma, Refractory Neuroblastoma | Phase 1, Phase 2 | Status: RECRUITING